‘Baby brain' is real. 3 things to know about what's happening to your brain
Pregnancy is one of the three Ps (puberty, pregnancy and perimenopause), a time when a person's brain undergoes physical changes due to hormones. d3sign//File via CNN Newsource
Science has pretty well established that the brain isn't static; it changes and adapts throughout our lives in response to life events in a process called neuroplasticity.
Researchers are discovering this is especially true of female brains, which get remodeled significantly during the three Ps: puberty (as do the brains of adolescent males), pregnancy and perimenopause.
All three transitions are a frequent butt of pop-culture jokes: the sulky, risk-taking teenager who only wants to be with friends; the scattered mom-to-be who leaves her cell phone in the fridge and can't remember where she parked the car; and the hormonal middle-aged woman who can't focus and spontaneously combusts with hot flashes.
But far from being laughable, these behavioral stereotypes are the external manifestations of big internal shifts, many of them linked to the effects of fluctuating hormones on the brain.
Cognitive neuroscientist Laura Pritschet, a postdoctoral fellow in the department of psychiatry at the University of Pennsylvania, is fascinated by how female hormones, including estrogen and progesterone, affect the brain's organization and functioning.
'The reason I chose that field is because I was a budding neuroscientist as an undergrad, interested in brain networks and obsessing over how intricate everything was in the brain to simply allow us to have a personality or remember things,' Pritschet told CNN Chief Medical Correspondent Dr. Sanjay Gupta recently, on his podcast Chasing Life.
'At the same time in my personal life, I was surrounded by menopausal women who were talking about their cognitive complaints and their attention issues,' she said. 'I thought we've got to connect these two together and understand this more.'
Pritschet even volunteered as a 'guinea pig' during graduate school, having her brain scanned and blood drawn for 30 days, across two complete reproductive cycles (both on and off birth control pills), to begin to answer the question of how the day-to-day fluctuations in hormones relate to the day-to-day changes in the brain.
Around this time, other researchers were studying what happens in the brain during pregnancy, Pritschet said, looking at the brain before and after gestation. They found many changes, but because the studies took a snapshot approach, many questions were left unanswered.
'If there's a 3 to 5% decrease in total gray matter volume, when is that occurring (during pregnancy), and how is it occurring?' Pritschet asked. 'We're missing huge gaps in what we call this metamorphosis.
'We know that the 40-week gestational window leads to these body adaptations to support the development of the fetus: We have increased plasma volume, immune function change, metabolic rate, oxygen consumption,' she said. 'What does this trajectory look like over gestation?'
To find out, Pritschet and her team tracked the brain changes in one woman, using MRI and blood draws, from pre-conception and fertility treatment throughout her pregnancy to two years postpartum. Their findings were published in the journal Nature Neuroscience in September.
'We saw this reduction in gray matter volume pretty much across the whole brain,' Pritschet explained. 'We saw increased white matter microstructure and ventricle size.' (Quick anatomy lesson: The brain is made up of gray and white matter. Gray matter is where most of the brain's thinking and processing takes place. White matter helps connect the different brain areas, allowing them to communicate with one another.)
'The inflection point was birth,' Pritschet said. 'We saw that those reductions persisted into postpartum, with slight recovery, meaning that certain areas of the brain showed this rise in gray matter volume in early postpartum. Others did not.'
Pritschet said this 'choreographed dance between major features of our brain' is in one respect a physical adaptation to the increased blood flow and swelling that comes with pregnancy.
Additionally, the changes may also be a preparation for the next stage: parenting.
'It's a fine-tuning of circuits,' she explained. 'We know that pregnancy is the lead-up to this time in your life where there's a lot of behavioral adaptation that has to occur, and new cognitive demands, and a new cognitive load.
'And so the idea here is that there is this pruning or this delicate rewiring to make certain networks or to make communication in the brain more efficient to meet the demands that are going to have to occur,' Pritschet said.
This theory is supported by earlier work. 'The first pinnacle papers that came out looking at neuroanatomy in human women from preconception to postpartum found that degree of change in gray matter volume — that sort of reduction — correlated with various … maternal behaviors (such as bonding). Again, that's all correlation,' she said.
'That's an area we need to do a lot more research on, and it needs a lot of context,' she said. 'But you can expect that if there's fine-tuning in these circuits that underlie cognitive or behavioral process, that the more fine-tuning it undergoes, the better performance you're going to have. That's the idea — but it's so much more complicated than that.'
What happens to the brain during pregnancy? Pritschet offers these three insights.
The only constant is change
The body is the outward sign of a lot of inner upheaval.
'Pregnancy is a transformative time in a person's life where the body undergoes rapid physiological adaptations to prepare for motherhood,' Pritschet said via email. 'But pregnancy doesn't just transform the body — it also triggers profound change to the brain and reflects another critical period of brain development.'
She called this remodeling an often-overlooked period of brain development that takes place well into a woman's adulthood.
How alarmed should women be?
Less gray matter may not sound very positive, but it happens for a reason.
'Despite what one might think, these reductions are not a bad thing, and in fact, are to be expected,' Pritschet said, noting that some of the losses are eventually regained. 'This change could indicate a 'fine-tuning' of brain circuits, not unlike what happens to all young adults as they transition through puberty and their brain becomes more specialized.'
These changes could also be a response to the high physiological demands of pregnancy itself, she said, 'showcasing just how adaptive the brain can be.'
These changes could affect future health and behavior
Mapping these changes could open the door to understanding an array of other neurological and behavioral outcomes including postpartum depression, headaches, migraines, epilepsy, stroke and parental behavior.
'The neuroanatomical changes that unfold during (pregnancy) have broad implications for understanding vulnerability to mental health disorders … and individual differences in parental behavior,' said Pritschet.
It may even provide critical insight into how the brain changes over a lifespan, she said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
an hour ago
- Globe and Mail
U.S. judge blocks National Science Foundation from slashing universities' federal funding
A federal judge on Friday prevented the National Science Foundation from sharply cutting research funding provided to universities in the latest legal setback to efforts by U.S. President Donald Trump's administration to slash government support of research at major academic institutions. U.S. District Judge Indira Talwani in Boston invalidated a policy NSF adopted in May that limited the ability of universities to be reimbursed for administrative and facility costs that indirectly support grant-funded research, ruling that it was 'arbitrary and capricious.' Spokespeople for NSF and the White House did not immediately respond to requests for comment on the ruling. NSF, a US$9 billion agency that funds scientific research, adopted the policy after having already canceled hundreds of grants out of step with the Republican president's priorities. His administration has also been freezing billions of dollars in government funding for numerous universities, including Harvard. NSF's policy, which was announced on May 2, set a cap on how much grant funding could go to cover indirect costs. NSF said funding for such costs could equal no more than 15% of the funding for direct research costs, regardless of what the costs actually were at universities. Historically, universities had negotiated with NSF and other agencies over the rate at which indirect costs could be reimbursed. The cap meant that for every $100 in funding going directly to a research grant award, universities would receive just $15 to cover overhead, such as the costs of maintaining lab space and paying for electricity and staff. The Trump administration said it sought through the policy to rein in spending on administrative overhead, which had grown to consume US$1.07 billion of NSF's annual US$4.22 billion grant-making budget for higher education institutions. That rate, though, is significantly lower than the indirect cost that many of the 69 research universities belonging to Association of American Universities had negotiated, which was often in the 50 per cent to 65 per cent range, the group's lawyers said. Talwani, an appointee of Democratic President Barack Obama, said in her Friday decision that the administration's 15 per cent rate was unlawful. The association along with two other academic trade groups and 13 schools sued in May to block the policy, after earlier convincing judges in Boston to block similar funding cuts at the National Institutes of Health and U.S. Department of Energy. The association did not immediately respond to a request for comment on the Friday decision. Among the schools that challenged NSF's funding cuts were the Massachusetts Institute of Technology, Princeton University, Brown University, the University of California, Carnegie Mellon University, Cornell University, the University of Michigan and the University of Pennsylvania. They argued that NSF's action, if allowed to stand, 'will badly undermine scientific research at America's universities and erode our nation's enviable status as a global leader in scientific research and innovation.' The U.S. Department of Defense has since also adopted a 15 per cent cap, which a judge on Tuesday temporarily blocked pending a hearing on July 2. He did so a day after a different judge in Boston ordered NIH to reinstate hundreds of grants for research on diversity-related topics nixed as part of the administration's purge of initiatives viewed as supporting 'diversity, equity and inclusion.'
Globe and Mail
4 hours ago
- Globe and Mail
Obesity Clinical Trials Appears Robust With 80+ Key Pharma Companies Actively Working in the Therapeutics Segment
DelveInsight's, ' Obesity Pipeline Insigh t 2025 ' report provides comprehensive insights about 80+ companies and 100+ pipeline drugs in Obesity pipeline landscape. It covers the Obesity pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Obesity therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive Obesity pipeline products in this space. Stay ahead with the latest insights! Download DelveInsight's comprehensive Obesity Pipeline Report to explore emerging therapies, key Obesity Companies, and future Obesity treatment landscapes @ Obesity Pipeline Outlook Report Key Takeaways from the Obesity Pipeline Report In June 2025, Carmot Therapeutics Inc. announced a Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of Once-Weekly CT-388 Administered Subcutaneously for 48 Weeks to Participants Who Are Overweight or Obese With Type 2 Diabetes Mellitus. In June 2025, Zomagen Biosciences Ltd. conducted a study to understand if taking VTX3232 alone or in combination with semaglutide is safe in participants diagnosed with Obesity. Approximately 160 patients will take VTX3232 Dose A, Placebo, VTX3232 Dose A in combination with semaglutide, or Placebo in combination with semaglutide. In June 2025, Boehringer Ingelheim organized a study is to find out whether a medicine called survodutide (BI 456906) helps people living with obesity disease to lose weight. Participants are divided into 3 groups by chance, like drawing names from a hat. 2 groups get different doses of survodutide and 1 group gets placebo. Placebo looks like survodutide but does not contain any medicine. In June 2025, Novo Nordisk A/S announced a study will look at how well CagriSema helps people living with obesity to lose weight and maintain the weight loss long-term. The study has 2 parts: The first part is called 'the main study' and the second part is called 'the extension study'. In the main study participants will either get CagriSema (a study medicine) or placebo (a dummy medicine that looks like CagriSema but has no active ingredient). Which treatment participants get is decided by chance. Participants are two times more likely to get CagriSema than placebo. If participants get CagriSema in the main study, participants will continue on CagriSema in the extension study. In June 2025, Hanmi Pharmaceutical Company Limited conducted a phase 3 study to evaluate efficacy and safety of HM11260C in adult obesity patients without diabetes mellitus. DelveInsight's Obesity pipeline report depicts a robust space with 80+ active players working to develop 100+ pipeline therapies for Obesity treatment. The leading Obesity Companies such as Zealand Pharma, Sciwind Biosciences, Genexine, Sirnaomics, Sparrow Pharmaceuticals, Shionogi, Regor Pharmaceuticals, Innovent Biologics, Pfizer, NodThera Limited, Boehringer Ingelheim, Fractyl Health, TransThera, Clearmind Medicine, PegBio, Biolingus, and others. Promising Obesity Therapies such as APHD-012, Bimagrumab, Semaglutide, CT-868, GLY-200, Bremelanotide, and others. Discover how the Obesity treatment paradigm is evolving. Access DelveInsight's in-depth Obesity Pipeline Analysis for a closer look at promising breakthroughs @ Obesity Clinical Trials and Studies Obesity Emerging Drugs Survodutide: Zealand Pharma Survodutide (BI 456906) is a long-acting glucagon/GLP-1 receptor dual agonist for once-weekly subcutaneous administration that activates two key gut hormone receptors simultaneously and may offer better efficacy than current single-hormone receptor agonist treatments. Survodutide is targeting the treatment of obesity and nonalcoholic steatohepatitis (NASH). Boehringer Ingelheim is advancing survodutide into three global Phase III trials in people living with overweight or obesity. Ecnoglutide: Sciwind Biosciences Glucagon-like peptide-1 (GLP-1) analogs are effective therapies in managing type 2 diabetes, obesity, and have demonstrated clinical potential as a treatment for NASH. Ecnoglutide (XW003) is a novel, cAMP signaling biased, long-acting GLP-1 analogue optimized for improved biological activity, cost-effective manufacturing, and once weekly dosing. Currently, the drug is in Phase III stage of its clinical trial for the treatment of Obesity. CT-868: Carmot Therapeutics CT-868 is a dual GLP-1 and GIP receptor modulator with a unique pharmacological profile optimized for improved tolerability at the GLP-1 receptor. The combined action of GLP-1 and GIP results in greater body weight loss and glucose control. CT-868 is dosed once daily to maximize efficacy and tolerability. CT-868 dual agonist candidate was discovered using the chemotype evolution technology as a peptide-small molecule hybrid compound, able to mimic the native GLP-1 hormone. In the Phase I trial, CT-868 demonstrated compelling pharmacodynamic activity across several clinical measures in overweight and obese healthy individuals a safe and generally well-tolerated profile. Carmot Therapeutics is now expanding the observations in overweight and obese patients with type 2 diabetes to demonstrate CT-868's effects on glycemic control, weight loss, and tolerability. Currently, the drug is in the Phase II stage of development to treat obesity. DD01: D&D Pharmatech DD01 is a proprietary, imbalanced dual agonist of GLP-1 and glucagon receptors with a half-life of 11 days in non-human primates. DD01 is being developed as a potential disease-modifying agent for obesity and liver fatty disease. Treatment with DD01 caused weight loss, reduced liver fat, and improved glucose tolerance in preclinical obesity, diabetes, and fatty liver models. In preclinical models of diabetes and nonalcoholic fatty liver disease (NAFLD), DD01 could reduce weight and blood sugar and improve insulin sensitivity and lipid and fat metabolism, which could ameliorate NASH. DD01 demonstrated greater efficacy in preclinical models than semaglutide, an approved GLP-1R receptor agonist; from a mechanical perspective, the effect of DD01 persisted after cessation of treatment. It is currently being evaluated in Phase I clinical trial to investigate the safety, tolerability, PK, and PD of DD01 administered by subcutaneous (SC) injection in overweight/obese subjects with type 2 diabetes mellitus and nonalcoholic fatty liver disease (NAFLD). The Obesity pipeline report provides insights into The report provides detailed insights about companies that are developing therapies for the treatment of Obesity with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Obesity Treatment. Obesity Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Obesity Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Obesity market. Get a detailed analysis of the latest innovations in the Obesity pipeline. Explore DelveInsight's expert-driven report today! @ Obesity Unmet Needs Obesity Companies Zealand Pharma, Sciwind Biosciences, Genexine, Sirnaomics, Sparrow Pharmaceuticals, Shionogi, Regor Pharmaceuticals, Innovent Biologics, Pfizer, NodThera Limited, Boehringer Ingelheim, Fractyl Health, TransThera, Clearmind Medicine, PegBio, Biolingus, and others. Obesity pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Obesity Products have been categorized under various ROAs such as Oral Parenteral Intravenous Subcutaneous Topical Obesity Products have been categorized under various Molecule types such as Recombinant fusion proteins Small molecule Monoclonal antibody Peptide Polymer Gene therapy Download DelveInsight's latest report to gain strategic insights into upcoming Obesity Therapies and key Obesity Developments @ Obesity Market Drivers and Barriers, and Future Perspectives Scope of the Obesity Pipeline Report Coverage- Global Obesity Companies- Zealand Pharma, Sciwind Biosciences, Genexine, Sirnaomics, Sparrow Pharmaceuticals, Shionogi, Regor Pharmaceuticals, Innovent Biologics, Pfizer, NodThera Limited, Boehringer Ingelheim, Fractyl Health, TransThera, Clearmind Medicine, PegBio, Biolingus, and others. Obesity Therapies- APHD-012, Bimagrumab, Semaglutide, CT-868, GLY-200, Bremelanotide, and others. Obesity Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Obesity Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Which companies are leading the race in Obesity drug development? Find out in DelveInsight's exclusive Obesity Pipeline Report—access it now! @ Obesity Emerging Drugs and Major Companies Table of Contents Introduction Executive Summary Obesity Overview Obesity Pipeline Therapeutics Obesity Therapeutic Assessment Late Stage Products (Phase III) Survodutide: Zealand Pharma Drug profiles in the detailed report….. Mid Stage Products (Phase II) CT-868: Carmot Therapeutics Drug profiles in the detailed report….. Early Stage Products (Phase I) DD01: D&D Pharmatech Drug profiles in the detailed report….. Preclinical and Discovery Stage Products Drug name: Company name Drug profiles in the detailed report….. Inactive Obesity Products Obesity Key Companies Obesity Key Products Obesity Unmet Needs Obesity Market Drivers Obesity Market Barriers Obesity Future Perspectives and Conclusion Obesity Analyst Views Obesity Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
Globe and Mail
5 hours ago
- Globe and Mail
Dr. Konstantinos Zarkadas Launches National Scholarship to Empower Aspiring Medical Leaders
Transformative Initiative Offers Financial Support to Future Physicians Committed to Service and Excellence GLEN COVE, NEW YORK - June 20, 2025 - In a bold step toward fostering the next generation of compassionate, driven medical professionals, Dr. Konstantinos Zarkadas, a respected leader in the healthcare sector, proudly announces the inauguration of the Dr. Konstantinos Zarkadas Scholarship for Future Doctors. This prestigious national scholarship aims to identify, support, and inspire undergraduate students who exhibit exceptional academic ability, a deep commitment to medicine, and a dedication to improving community health outcomes. The scholarship will award a one-time $1,000 grant to a single undergraduate student who meets the rigorous eligibility criteria. Applications are now open, with the deadline set for November 15, 2025. The recipient will be publicly announced on December 15, 2025. 'The future of medicine depends on individuals who lead with both intellect and empathy,' said Dr. Konstantinos Zarkadas. 'Through this scholarship, I hope to ease the financial burdens faced by aspiring doctors while encouraging them to embrace the calling of medical service with integrity, leadership, and vision. This is not just an award—it is an investment in the future of healthcare.' Dr. Zarkadas brings over two decades of experience in clinical practice and medical leadership. His academic journey, which includes a degree in Psychology from Hunter College, advanced medical training in the Dominican Republic, and a Master of Health Administration from Columbia University, has shaped his unique perspective on holistic and inclusive healthcare delivery. Currently serving as Chief Medical Officer at Arch Sleep Apnea Solutions and leading multiple medical practices, Dr. Konstantinos Zarkadas is deeply committed to transforming community health through culturally competent and patient-centered care. The Dr. Konstantinos Zarkadas Scholarship for Future Doctors has been thoughtfully designed to recognize students who combine academic excellence with a strong sense of social responsibility. Eligible applicants must meet the following criteria: Current Undergraduate Enrollment: Students must be enrolled at an accredited U.S. college or university. Pre-Medical Focus: Candidates must be pursuing a pre-med track or a closely related field, with clear intent to enter medical school. Academic Performance: A minimum cumulative GPA of 3.5 is required. Residency: Open to U.S. citizens and permanent residents. Leadership and Service: Applicants should demonstrate leadership potential and a history of meaningful community involvement. Commitment to Medicine: Candidates must clearly articulate their passion for medicine and dedication to a career in healthcare. Fluent in English, Greek, and Spanish, Dr. Konstantinos Zarkadas has long been an advocate for health equity and multicultural competence in medical practice. His past collaborations with organizations like Somos Community Care ACO and his leadership role in medical education at The New Parkway Hospital underscore his unwavering mission to mentor and empower the next wave of healthcare providers. Unlike many geographically limited programs, this scholarship is open to qualified students nationwide. Applicants must submit an original essay reflecting on their motivation to pursue medicine, their experiences in community service, and their vision for contributing meaningfully to the healthcare field. This narrative component is central to the selection process, allowing students to highlight not only their achievements but their potential for lasting impact. Comprehensive application guidelines and submission instructions can be found at: By championing students who exemplify both academic rigor and humanitarian values, the Dr. Konstantinos Zarkadas Scholarship for Future Doctors seeks to elevate the standards of tomorrow's medical profession. This initiative affirms Dr. Zarkadas's enduring belief that investing in education and ethical leadership is the surest path to a stronger, more inclusive American healthcare system. Media Contact Company Name: Dr. Konstantinos Zarkadas Scholarship Contact Person: Dr. Konstantinos Zarkadas Email: Send Email City: GLEN COVE State: NEW YORK Country: United States Website:
